|Bid||19.13 x 1000|
|Ask||19.15 x 900|
|Day's Range||18.95 - 19.61|
|52 Week Range||12.19 - 27.55|
|Beta (3Y Monthly)||2.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.90|
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced the completion of an interim statistical assessment of its pivotal KALM-2 Phase 3 global clinical trial of KORSUVA™ (CR845/difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Based on the Independent Data Monitoring Committee’s (IDMC) recommendation, the size of the trial will be increased by approximately 20 percent, from an original enrollment target of 350 patients to 430 patients, to maintain the pre-specified statistical power of 90 percent or greater on the trial’s primary endpoint.
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
STAMFORD, Conn., Sept. 26, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.
The big shareholder groups in Cara Therapeutics, Inc. (NASDAQ:CARA) have power over the company. Institutions will...
The cannabis industry enjoyed tremendous investor enthusiasm in 2018, fueled in large part by major developments which seemed to open up the space for new opportunities. In spite of the fact that cannabis stocks overall failed to perform up to expectations last year, 2019 has already revealed continued anticipation regarding this growing industry. If cannabis stocks are to thrive going forward, it's likely that many companies will have some growing up to do.
The past several months haven't been particularly kind to cannabis stocks, as the hope (and hype) of the long-term potential collides with short-term reality. That is, most of these companies have spent heavily to take the lead in a highly contested race, but don't yet have the scale needed to drive actual profits.That day is still coming, at least for several of the names in the business. The question is, which ones will be left standing, picking up the pieces of an ever-growing industry?Nobody knows for sure; it's unlikely that even the companies' chiefs are entirely convinced themselves they're being built to last. But, with the marijuana industry having only scratched the surface of what it can be, and likely will be, there's little doubt that at least some of these names could double their current values.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10 Best Marijuana Stocks to Buy Now Here's a rundown of the top ten cannabis stocks most likely to dish out a triple-digit gain, sooner or later. Canopy Growth (CGC)Source: Shutterstock It's arguably the name that started cannabis-mania, as Canopy Growth (NYSE:CGC) was the first name to attract a major partner's money. In October 2017, booze company Constellation Brands (NYSE:STZ) bought a 10% stake in Canopy Growth, then in August of last year an additional $4 billion investment in CGC stock made Constellation a near-40% stakeholder. The underlying plan was ultimately ensuring access to a supply for the time when a launch of a cannabis-infused beverage made sense.Since then, the relationship became so strained that a frustrated Constellation management team forced Canopy's CEO Bruce Linton out of the role. An aggressive acquisition spree chewed up more money well before it was ready to drive a return on the investment.Still, the dozen or so acquisitions Canopy Growth has made over the course of the past year gives the organization a wide array of horizontally and vertically minded ways to monetize cannabis at some point in the future. Charlotte's Web Holdings (CWBHF)Source: Shutterstock Don't let the OTC listing fool you. With a market cap of nearly $1 billion and $86 million worth of revenue for its past four reported quarters, Charlotte's Web Holdings (OTCMKTS:CWBHF) is a more legitimate company than many of its exchange-listed counterparts. An over-the-counter listing is just less of a hassle.Charlotte's Web Holdings is uniquely positioned. It's not waiting on legalization of recreational marijuana in the U.S. because it doesn't have to. It already offers CBD oil, and capsules, in the United States and can deliver their product -- legally -- in the mail to anywhere in the U.S. * The 10 Best Cheap Stocks to Buy Right Now Perhaps more compelling, Charlotte's Web Holdings is already turning a profit. Granted, it's not a jaw-dropping bottom line. Last quarter's net income was a modest $2.2 million. It's evidence that the business can be profitable though. Net margins should improve as the company scales up. Aurora Cannabis (ACB)Source: Shutterstock Canopy Growth may be best known, for better or worse, as a rapid-fire buyer of smaller cannabis outfits with the aim of building a large conglomerate. But, Aurora Cannabis (NYSE:ACB) is certainly no slouch on that front. It recently closed on the Hempco deal first announced in April, rounding outs rather robust portfolio too.It was self-serving to be sure, but Aurora CEO Terry Booth wasn't off-base when he said of the closed Hempco acquisition "we have assembled a world-class portfolio of high-quality hemp assets that together form the basis of a strong new operating division that will develop CBD-from-hemp around the world."Aurora Cannabis is also an interesting play simply because it's not trying to be all things to all people. Although it's not terribly easy to distinguish just yet, this company is focused more on medical marijuana, and less on recreational usage.It matters. Although it's more difficult, prices and therefore margins are stronger within the medical marijuana market, where Aurora is quickly demonstrating proficiency. GW Pharmaceuticals (GWPH)Source: Shutterstock It's a name that is often left out of the discussion because (1) it's not looking to capitalize on the ongoing legalization of recreational marijuana, and (2) it has been around for years. But GW Pharmaceuticals (NASDAQ:GWPH) has absolutely earned a spot on any list of cannabis stocks positioned to double in the foreseeable future.GW Pharmaceuticals is, as the name suggests, a pharmaceutical developer. It has worked diligently to extract the full health benefits of cannabidiol, or CBD, for prescription use. It convinced the Food and Drug Administration of that potential in June of last year, securing approval for CBD-based Epidiolex as a means of treating seizures … the first CBD-based drug permitted in the U.S. * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The response has been nothing short of incredible. Some observers were expecting Epidiolex to reach a total of $65 million, total, this year. By the end of the second quarter, GW Pharmaceuticals had actually sold $102 million worth of the drug. Hexo (HEXO)Source: Shutterstock It wasn't one of the names batted around a great deal when marijuana stocks were all the rage during the middle of last year. Since then, Hexo (NYSE:HEXO) has managed to make some noise for itself.Hexo, for the unfamiliar, is building itself from the ground up, specifically to cultivate partnerships with bigger players than can carve out market share better than it ever could on its own. It calls it a "hub and spoke" model, where it serves as the hub and supplies cannabis to various partners at the other end of the spoke. There's room for several.It already has one such partner: Molson Coors Brewing (NYSE:TAP) is looking to build a cannabis beverage brand with Hexo. Other partners with other focal points will be added in time.The hard part about the strategy is, Hexo doesn't appear to be in a hurry to execute it. That patience, however, may ultimately be to the company's advantage. Tilray (TLRY)Source: Shutterstock It's curious. The consensus rating on Tilray (NASDAQ:TLRY) shares is only a little better than a 'Hold.' But, the consensus target is a healthy $64.40 per share. That's more than twice the current price of TLRY stock.It's not an unusual nuance within the cannabis industry at this time. Analysts aren't quite sure how to value these names, most of which are startups, and all of which are being lifted at least a little by hype. It's not easy to see the line dividing what's likely, and what's possible.Still, the average target for Tilray shares marks one of the biggest upsides the professionals expect to see come to fruition. * 7 Fintech ETFs to Buy Now for Fabulous Financial Exposure Tilray offers a variety of products, including extracts and dried flower, for users seeking THC as well as CBD. It also sells products on five different continents, making it a geographically diverse player. Cara Therapeutics (CARA)Source: Shutterstock As was the case with GW Pharmaceuticals, Cara Therapeutics (NASDAQ:CARA) has largely been omitted from the discussion of cannabis stocks as a whole because it's not a newcomer catering mostly to recreational users. It's still a cannabis name though, or will be, eventually.Cara's claim to fame at this time is a developmental drug currently just referred to as CR845. It's a prospective alternative to opioids, which are effective painkillers, but also highly addictive. CR845 also has absolutely nothing to do with cannabis.Cara Therapeutics' CR701, however, is a prospective painkiller that specifically uses cannabinoid agonists to block the body's pain receptors. While still years away from commercialization, the clinical trial setting certainly legitimizes cannabis as real medicine. OrganiGram Holdings (OGI)Source: Shutterstock If nothing else, OrganiGram Holdings (NASDAQ:OGI) has earned a look because it's one of the few names in the cannabis business that's profitable. Indeed, with its numbers reported in July, it has been profitable for four straight quarters.The underpinnings for that unusual claim in the cannabis realm largely reflects the company's growing acumen. Even though last quarter's cash production costs grew from 65 cents per gram to 95 cents per gram, that's still less than the $1.42 per gram Aurora had to spend to supply itself, or the $1.48 Tilray laid out to grow its own supply. * The 10 Best Marijuana Stocks to Buy Now Still, the big cost jump last quarter? Don't read too much into it. The costs were associated with an experiment designed to further improve yield. It failed, so the company won't be attempting it again. Medipharm Labs (MEDIF)Source: Shutterstock As was the case with Charlotte's Web Holdings, don't be put off by the OTC listing of Medipharm Labs (OTCMKTS:MEDIF). This company is also on firmer footing than many of its exchange-listed rivals, even if most cannabis investors have never heard of it.Medipharm Labs specializes in one narrow sliver of the budding cannabis arena … extraction. Leveraging technology with experience, this company can turn raw marijuana into pure cannabis that meets the exacting standards most CBD suppliers expect in the current, scrutinizing environment.It's still bleeding money in a big way, here at the industry's infancy. Patience is merited though. This year's top line is projected to grow nearly 40%, followed by another 32% revenue leap next year.That still won't be enough to drag Medipharm out of the red, but scale should pay off soon enough. Cronos Group (CRON)Source: Shutterstock Finally, add Cronos Group (NASDAQ:CRON) to your list of cannabis stocks with the potential to double at some point in the future.Cronos Group does a little of everything, from cannabis research to product development consumer sales. It operates three brands: Peace Naturals, Cove and Spinach. And, like Tilray, it has a presence on five different continents.Perhaps the most bullish argument for CRON stock at this time, however, is the recently initiated coverage from Piper Jaffray. Analyst Michael Lavery notes "We expect Cronos to have modest near-term revenues from Canadian cannabis production, but believe it has significant potential growth opportunities with CBD products in the US, including through its pending acquisition of the Lord Jones brand." * 7 Marijuana Penny Stocks That I May Buy Its partnership with Altria Group (NYSE:MO) also bodes well, even if it has accomplished little so far.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post 10 Marijuana Stocks That Could See 100% Gains, If Not More appeared first on InvestorPlace.
Deal Showcases the Potential of Peptelligence® as the "Gold Standard" Technology for Developing Oral Formulations of Peptide-Based Drugs Oral KORSUVA™ is Currently the Subject of Three Separate ...
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has entered into a non-exclusive commercial license agreement with Enteris BioPharma, Inc. for oral formulation rights to Enteris’ Peptelligence® Technology. “We are pleased to take another important step in advancing Oral KORSUVA™ as a potential novel treatment for chronic pruritus by entering into this commercial formulation license,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.
Derek Chalmers became the CEO of Cara Therapeutics, Inc. (NASDAQ:CARA) in 2004. First, this article will compare CEO...
STAMFORD, Conn., July 31, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
STAMFORD, Conn., July 29, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical.
STAMFORD, Conn., July 24, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical.
Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In addition, Cara Therapeutics expects to grant certain of the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Study now fully enrolled; topline data expected in 4Q 2019 - STAMFORD, Conn., July 22, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on.
CFO & Chief Strategy Officer of Cara Therapeutics Inc (30-Year Financial, Insider Trades) Mani Mohindru (insider trades) sold 37,431 shares of CARA on 07/15/2019 at an average price of $25 a share. Continue reading...
Investing in biotech stocks can generate substantial returns. If data results meet key targets, or drug applications are accepted, share prices can soar. Unfortunately the reverse is also true. That means investors have to be particularly careful when it comes to biotech stocks. The following four stocks all show a Strong Buy Street consensus- based on ratings received over the last three months. They also boast significant upcoming catalysts this quarter- that could potentially send share prices soaring. Let’s take a closer look at each stock now: 1\. Intercept Pharmaceuticals (ICPT)Intercept Pharma is trying to help patients with progressive non-viral liver diseases. The company already has one drug on the market (for primary biliary cirrhosis), and recently released positive results from the Phase 3 REGENERATE trial in NASH Fibrosis. Nash is a chronic condition in which the buildup of fat and inflammation in the liver may eventually lead to severe scarring called fibrosis. It is currently the second leading cause of liver transplant in the US- making it a very lucrative opportunity for drug companies. Intercept has an early mover advantage here. The company plans to submit an NDA [new drug application] in 3Q19 and an MAA [marketing authorization application] in 4Q19. “Obeticholic Acid will likely be the first to market in NASH and is the only drug to have demonstrated a fibrosis benefit” cheers Needham analyst Alan Carr. “We acknowledge certain potential safety and tolerability limitations, but nevertheless expect the drug to have an important role in NASH therapy over the next several years” says the analyst. Overall the stock has a ‘Strong Buy’ Street consensus, with 5 recent buy ratings vs just 1 hold rating. Meanwhile the average analyst price target of $148 indicates huge upside potential of 113%. >>Click Here to see the full list of ICPT Analyst Ratings 2\. Rhythm Pharmaceuticals (RYTM)Rhythm is developing treatments for rare genetic deficiencies that result in life-threatening metabolic disorders. The big news here is that Rhythm is expected to announce results in 3Q19 from two Phase 3 trials of setmelanotide in POMC and LEPR Deficiency. There are currently no approved drugs for these diseases- and no other drugs in development.“We anticipate a positive outcome for both trials based on Phase 2 data demonstrating a profound and durable impact on appetite and weight” writes Carr. The analyst assumes US approval and launch in 4Q20 (EU 2021) and peak worldwide sales of around $265M in 2032.“Considering recent weakness, we believe the stock is attractive ahead of Phase 3 POMC and LEPR Deficiency trial results. We believe there is even more room for upside for the stock as the company completes label expansion trials in 2020+” enthuses Carr. Most notably label expansion Phase 3 trial in Bardet-Biedl/Alstrom Syndromes remains on track for results in 2H20. Success here adds another $485M in peak sales potential. “Additional patient populations under evaluation in a Phase 2 trial push peak sales above $1B” writes Carr. RYTM has four consecutive recent buy ratings from the Street, with an average price target of $40 (95% upside potential). >>Click Here to see the full list of RYTM Analyst Ratings 3\. Moderna Inc (MRNA)Moderna is hoping to create a new generation of transformative medicines for patients. The company’s approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease. Encouragingly, all seven analysts covering MRNA rate the stock a buy- so no hold or sell ratings here. “We expect Moderna to provide updates on Cytomegalovirus (CMV), Chikungunya, and Methylmalonic Acidemia (MMA) programs by YE19” writes the analyst.While the commercial opportunity in Chikungunya is modest, he believes PK/PD data from the Phase 1 trial will provide valuable insight into the overall predictability of several other mRNA drugs in development at the company.“The stock has fallen substantially from its peak in May 2019. We believe there is an opportunity for upside in 2H19 as the company announces data from the above CMV, Chikungunya, and MMA programs” Carr concludes. Indeed, the Street’s $30 average price target suggests share prices can double in the coming months. >>Click Here to see the full list of MRNA Analyst Ratings 4\. Cara Therapeutics (CARA)Cara Therapeutics has surged 30% in last the three months. In May the company announced positive results from the first of two Phase 3 trials of IV Korsuva in Chronic Kidney Disease (CKD) dialysis patients with pruritus. Pruritus refers to the severe itching of the skin, a common and distressing symptom for patients with chronic kidney disease. Cara Therapeutics CEO Derek Chalmers noted at the time that the company was "particularly encouraged by the early [anti-itching] response with Korsuva injection." Now investors are keeping a close eye on results from the second trial (KALM-2) and from a Phase 2 trial of oral Korsuva in non-dialysis patients with CKD pruritus- both expected in 2H19. “We anticipate a positive outcome for both trials” comments Carr, adding that the recent results point to a favorable outcome for the KALM-2 trial. “We believe the outcome is also a positive indicator for the oral Korsuva programs in CKD pruritus, Liver Disease pruritus, and Atopic Dermatitis, all of which have large commercial opportunities.”Bottom line: “The stock is substantially undervalued.” All six analysts polled are bullish on CARA right now. Meanwhile the average analyst price target stands at $33 (30% upside potential). >>Click Here to see the full list of CARA Analyst RatingsDiscover the latest ratings from top analysts in any sector you choose
"Lowell Herb Co." is launching the nation's first ever cannabis cafe. Backed by Miley Cyrus, the cafe gives its customers a place to legally purchase and consume cannabis products. Lowell Herb Co.'s Director Kevin Brady joins Yahoo Finance's Zack Guzman and Heidi Chung, along with “The Morning Brew” Business Editor and Podcast Host Kinsey Grant, to discuss.